Neeraj Agarwal MDProfessor of Medicine, Huntsman Cancer Institute (HCI) Presidential Endowed Chair of Cancer Research; Co-Leader, HCI Experimental Therapeutics Program (CCSG Program); Director, Center of Investigational Therapeutics; Director, Genitourinary Oncology Program, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah
Dr. Neeraj Agarwal, a specialist in genitourinary cancer, is Associate Professor of Medicine in the Division of Oncology at the University of Utah School of Medicine in Salt Lake City, where he is also the Director of the Genitourinary Oncology Program. He is the Co-Leader of the Urologic Oncology Multidisciplinary Program and the Associate Director of Clinical Trials (solid tumors) at the Huntsman Cancer Institute.
Dr. Agarwal received his medical degree from All India Institute of Medical Sciences in New Delhi. After completing a residency in internal medicine and a fellowship in geriatric medicine at the University of Iowa, he went on to complete a hematology–oncology fellowship at Huntsman Cancer Institute and the University of Utah School of Medicine.Dr. Agarwal is a member of several professional societies, including the American Society of Clinical Oncology, the American Association of Cancer Research (AACR), and the Southwest Oncology Group (SWOG). He has published widely, having authored over 100 peer-reviewed articles and book chapters.
DisclosuresDr. Agarwal discloses the following:
Consultancy to: Astellas, Astra Zeneca, Bayer, Bristol Myers Squibb, Clovis, Eisai, Eli Lilly, EMD Serono, Exelixis, Foundation Medicine, Genentech, Janssen, Merck, Nektar, Novartis, Pfizer, Pharmacyclics, and Seattle Genetics.
Research funding to his institution: Astra Zeneca, Bavarian Nordic , Bayer, Bristol Myers Squibb, Calithera, Celldex, Clovis, Eisai, Eli Lilly, EMD Serono, Exelixis, Genentech, Glaxo Smith Kline, Immunomedics, Janssen, Medivation, Merck, Nektar, New Link Genetics, Novartis, Pfizer, Prometheus, Rexahn, Roche, Sanofi, Seattle Genetics, Takeda, and Tracon.
Recent Contributions to PracticeUpdate:
- Histological Subtypes and Response to PD-1/PD-L1 Blockade in Advanced Urothelial Cancer
- Time to Second Progression Among Patients With Metastatic Castration-Sensitive Prostate Cancer Treated With Apalutamide
- Cabozantinib Plus Atezolizumab for Patients With Metastatic Castration-Resistant Prostate Cancer
- ESMO: Critical Data on Apalitumide in Castrate-Sensitive Prostate Cancer
- ESMO: Key Trials in Prostate Cancer
- FGFR3 Inhibition by Infigratinib for Upper Tract Urothelial Cancer
- Consideration of Adverse Events and QoL in Planning Adjuvant Therapy for Localized RCC
- Clinical Implications of New Data on Apalutamide + ADT in Castrate-Sensitive Prostate Cancer
- Rationale and Promise of PARP Inhibitors in Castrate-Resistant Prostate Cancer
- Clinical Data and Recommendations for Atezolizumab vs Sunitinib for Metastatic Renal Cell Carcinoma.